Previous 10 | Next 10 |
home / stock / azncf / azncf news
2024-03-08 17:15:31 ET Summary AstraZeneca PLC has seen a modest 3% price rise in the past year, but there are positive factors that could drive price upside in 2024. The company has improved revenue guidance for 2024, after guidance beating 2023 numbers. It also sustains a health...
2024-02-24 20:53:46 ET Summary Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There are four other data readouts/presentations expected ...
2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...
2024-02-22 21:01:24 ET Summary Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar. In reviewing FY23 results and commentary, we discuss key points like SELECT outcomes; CagriSema progress; and expansion into cardiovascular disease. Though expen...
2024-02-21 11:51:31 ET Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a ...
2024-02-20 17:40:54 ET Summary I have been tracking M&A stocks for almost 30 years and sharing insights with the Seeking Alpha community. The article focuses on M&A funds that own at least 3.5% of a stock involved in a merger or buyout. I highlight several stocks, incl...
2024-02-20 11:05:26 ET More on AstraZeneca PLC AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca PLC 2023 Q4 - Results - Earnings Call Presentation AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth Daiichi Sankyo-AstraZeneca ...
2024-02-19 07:36:17 ET Read the full article on Seeking Alpha For further details see: Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.
2024-02-18 02:05:00 ET Summary LianBio plans to stop all its operations by the end of 2024 and will distribute a $4.80 dividend/share ($528M) to its shareholders. Yiviva signed a memorandum of understanding with AstraZeneca China for an R&D collaboration at AstraZeneca’...
2024-02-15 15:00:53 ET Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has init...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...